Differential expression of TRAIL and its receptors in benign and malignant prostate tissues
JOURNAL OF UROLOGY, vol.177, no.1, pp.359-364, 2007 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 177 Issue: 1
- Publication Date: 2007
- Doi Number: 10.1016/j.juro.2006.08.087
- Journal Name: JOURNAL OF UROLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.359-364
- Keywords: prostate, prostatic neoplasms, TNF-related apoptosis-inducing ligand, apoptosis, gene therapy, CANCER IN-VITRO, INDUCED APOPTOSIS, GENE-THERAPY, CELLS, MECHANISMS, CARCINOMA, VIVO
- Akdeniz University Affiliated: Yes
Abstract
Purpose: Because TRAIL (tumor necrosis factor related apoptosis inducing ligand) selectively kills cancer cells without damaging normal cells, a gene therapy approach using TRAIL is feasible for treating patients with cancer. However, recent publications suggest that significant portions of human tumors appear to be TRAIL resistant. Furthermore, there is some controversy about whether TRAIL receptor composition influences TRAIL sensitivity in cancer cells. Our recent studies suggest. that TRAIL receptor composition is the major modulator of TRAIL sensitivity, as demonstrated using prostate, breast and lung cancer cells. We investigated TRAIL and TRAIL receptor expression profiles during prostate carcinogenesis to evaluate their potential as biomarkers and predict the feasibility of a related gene therapy approach.